Sign up Australia
Proactive Investors - Run By Investors For Investors

Critical year ahead of drug development for Midatech Pharma

Jim Phillips, chief executive at Midatech Pharma Plc (LONMTPH, NASDAQ:MTP), updates Proactive's Andrew Scott on their three high-value, lead programmes progressing through pre-clinical and clinical development.

The key to each of those programmes is Midatech’s technology which allows it to precisely deploy drugs into the body.

Its two platforms – carbohydrate-coated gold nano-particles and its sustained release system – are about getting medicines to the right place in the right quantities at the right time.

Last month they secured a US$15mln, four-year senior loan facility to help bankroll the programmes.

 
Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event, Sydney , 19 November 2018. Register here »
View full MTPH profile View Profile

Midatech Pharma Plc Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use